GSK 1363089
Chemical Name: N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
Purity: ≥98%
Biological Activity
GSK 1363089 is a potent inhibitor of MET, VEGFR2, Ron and AXL (IC50 values are 0.4, 0.9, 3 and 11 nM, respectively). Also potently inhibits Tie-2, Flt-1, Flt-3, Flt-4, KIT, PDGFRα and PDGFRβ. Inhibits migration and invasion of B16F10 melanoma cells in vitro. Suppresses B16F10 tumor growth and metastasis in mice. Orally available.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
AXL inhibitors in cancer: A medicinal chemistry perspective.
Myers et al.
J.Med.Chem., 2016;59:3593 -
Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria et al.
Cancer Res., 2015;75:134 -
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian et al.
Cancer Res., 2009;69:8009
Product Datasheets
Reconstitution Calculator
Molarity Calculator
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for GSK 1363089
There are currently no reviews for this product. Be the first to review GSK 1363089 and earn rewards!
Have you used GSK 1363089?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
